Copyright © 2016

Aridis Pharmaceuticals, Inc.

5941 Optical Court, San Jose, CA 95138

Phone: 408-385-1742

Site Map

Privacy Policy

Financial Conflict of Interest Policy

Back to top

Previous page

News

01-09-17

Aridis Pharmaceuticals Receives Award from the Cystic Fibrosis Foundation Therapeutics to Advance Panaecin™.

01-05-17

Aridis Pharmaceuticals Reports Positive Clinical Data from Phase 1/2a Study of Human Monoclonal Antibody AR-301 for Treating Pneumonia.

09-21-16

Aridis Pharmaceuticals CEO Invited to Speak on Infectious Disease Panel at 2016 Anti-Infectives Rx Conference.

07-11-16

Aridis Pharmaceuticals Expands the Company’s Clinical Advisory Board; Adds Three Industry Veterans with Unique Expertise in the Field.

04-18-16

Aridis Pharmaceuticals Strengthens Board of Directors with Former Wyeth (now Pfizer) President of R&D Robert Ruffolo, Jr..

02-02-16

Aridis Pharmaceuticals to Present at BIO CEO & Investor Conference 2016.

01-07-16

Aridis Pharmaceuticals Reports Positive Phase 1 Clinical Results for Aerucin® for Treating Hospital-Acquired and Ventilator-Associated Pneumonia.

01-06-15

Aridis Pharmaceuticals to Present at Biotech Showcase 2016.

10-13-15

Aridis Pharmaceuticals Receives Multiple NIH Grants.

09-15-15

Aridis Pharmaceuticals Receives FDA Fast Track Designation for AR-301 for Acute Pneumonia caused by Staphylococcus aureus.

07-14-15

Aridis Pharmaceuticals Appoints Fred Kurland as Chief Financial Officer.

07-08-15

Aridis Pharmaceuticals Expands Phase 2a Trial Into the U.S. for Monoclonal Antibody AR-301 for the Treatment of Acute Pneumonia.

06-30-15

Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia.

04-09-15

Aridis Pharmaceuticals Adds Craig Gibbs, Ph.D., M.B.A., to Board of Directors.

03-26-15

Aridis Pharmaceuticals Commences Phase 1 Clinical Study of Aerucin Monoclonal Antibody for Acute Pneumonia.

03-23-15

Aridis Pharmaceuticals Appoints Paul-Andre de Lame, M.D., as Chief Medical Officer.

01-06-15

Aridis Pharmaceuticals to Present at Biotech Showcase 2015.

11-26-14

Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board.

11-19-14

Aridis Pharmaceuticals' Novel Antibody Therapy for Hospital-Acquired Pneumonia Selected as a Top Infectious Disease Project to Watch.

09-16-14

Aridis Pharmaceuticals Raises $6.75 Million in Oversubscribed Private Placements.

10-30-13

Aridis Awarded National Institutes of Health (NIH) Contract to Develop Gallium-Based Anti-Infectives.

05-15-13

Aridis Pharmaceuticals Announces the Acquisition of Monoclonal Antibody Products and Technologies from Kenta Biotech.

08-22-12

Manufacturing agreement with a commercial partner is completed, paving the way for GMP manufacturing of AerucinTM anti-Pseudomonas aeruginosa monoclonal antibody.

08-20-12

Aridis completed a major research and development agreement with a multi-national partner to develop advanced vaccine formulation for a childhood vaccine.

08-14-12

Two key formulation and pharmaceutical process technologies patents [8,241,866 and 8,268,354] are issued by the US Patent Office.

02-08-12

Aridis receives notice of award of a NIH grant to develop room temperature stable oral thin film formulation for vaccine against anthrax and plague.

PHARMACEUTICALS

Breakthrough Therapies for

Antibiotic Resistant Infections

Aridis